Back to top
more

Verastem (VSTM)

(Delayed Data from NSDQ)

$9.38 USD

9.38
42,668

+0.17 (1.79%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $9.35 -0.03 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VSTM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Verastem, Inc. [VSTM]

Reports for Purchase

Showing records 241 - 260 ( 264 total )

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 241

03/27/2013

Company Report

Pages: 6

2012 Results; All Engines Engaged, Reiterate Buy and $18 PT

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 242

03/13/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 243

03/13/2013

Company Report

Pages: 28

Targeting the Root of the Tumor, Initiating Coverage at Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 244

08/13/2012

Daily Note

Pages: 3

Reports FY2Q12 Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 245

08/13/2012

Company Report

Pages: 6

Reports FY2Q12 Results

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 246

07/23/2012

Daily Note

Pages: 3

Updating Our Models to Reflect Development Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 247

07/23/2012

Company Report

Pages: 14

Updating Our Models to Reflect Development Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 50.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 248

07/13/2012

Daily Note

Pages: 5

Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 249

07/13/2012

Daily Note

Pages: 3

Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 250

07/12/2012

Daily Note

Pages: 3

Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 251

07/12/2012

Company Report

Pages: 6

Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 252

07/11/2012

Company Report

Pages: 4

Looking Ahead to Tomorrow’s R&D Update from Verastem

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 253

07/11/2012

Daily Note

Pages: 3

Looking Ahead to Tomorrow’s R&D Update from Verastem

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 254

05/31/2012

Daily Note

Pages: 3

Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 255

05/31/2012

Company Report

Pages: 4

Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 256

05/17/2012

Industry Report

Pages: 3

2012 ASCO PLANNER

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 257

04/14/2012

Daily Note

Pages: 3

FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 258

04/14/2012

Company Report

Pages: 9

FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 259

04/03/2012

Company Report

Pages: 4

Compounds and Stem Cell Science Take Center Stage at AACR

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Verastem, Inc.

Industry: Medical - Biomedical and Genetics

Record: 260

04/03/2012

Daily Note

Pages: 3

Compounds and Stem Cell Science Take Center Stage at AACR

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party